CJC-1295/Ipamorelin Blend

A 10 mg blend per vial containing CJC-1295 without DAC 5 mg and ipamorelin 5 mg. For in-vitro research only.

• The CJC constituent is described as a tetrasubstituted form of the 1-29 fragment carrying an N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus, the group that conjugates to serum albumin. [1]
• Detection work lists CJC-1295 and CJC-1295 with drug affinity complex as separate target analytes, so the two forms are distinguished analytically and not by name. [2]
• The second constituent is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, which released growth hormone from primary rat pituitary cells with an EC50 of 1.3 nmol/l through a GHRP-like receptor. [3]
• Once conjugated the CJC construct behaves as a macromolecule of undefined mass, which is why the cited screens used immuno-polymerase chain reaction or immuno-affinity capture rather than top-down mass spectrometry. [4]

Compound

CJC-1295/Ipamorelin Blend

Purity

99.20% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

10 mg

Catalog / lot

RV-0036 / RV-24-0036-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.